- Home
- DVAX vs DMAC Comparison
DVAX vs DMAC Comparison
Compare DVAX & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- DMAC
- Stock Information
- Founded
- DVAX 1996
- DMAC 2000
- Country
- DVAX United States
- DMAC United States
- Employees
- DVAX N/A
- DMAC N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- DVAX Health Care
- DMAC Health Care
- Exchange
- DVAX Nasdaq
- DMAC Nasdaq
- Market Cap
- DVAX N/A
- DMAC 178.0M
- IPO Year
- DVAX 2004
- DMAC N/A
- Fundamental
- Price
- DVAX $10.27
- DMAC $3.76
- Analyst Decision
- DVAX Buy
- DMAC Strong Buy
- Analyst Count
- DVAX 4
- DMAC 2
- Target Price
- DVAX $26.25
- DMAC $8.00
- AVG Volume (30 Days)
- DVAX 1.8M
- DMAC 307.4K
- Earning Date
- DVAX 08-05-2025
- DMAC 08-06-2025
- Dividend Yield
- DVAX N/A
- DMAC N/A
- EPS Growth
- DVAX N/A
- DMAC N/A
- EPS
- DVAX N/A
- DMAC N/A
- Revenue
- DVAX $294,620,000.00
- DMAC N/A
- Revenue This Year
- DVAX $21.18
- DMAC N/A
- Revenue Next Year
- DVAX $16.83
- DMAC N/A
- P/E Ratio
- DVAX N/A
- DMAC N/A
- Revenue Growth
- DVAX 24.76
- DMAC N/A
- 52 Week Low
- DVAX $9.22
- DMAC $2.80
- 52 Week High
- DVAX $14.63
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- DVAX 54.20
- DMAC 47.18
- Support Level
- DVAX $9.79
- DMAC $3.48
- Resistance Level
- DVAX $10.38
- DMAC $3.99
- Average True Range (ATR)
- DVAX 0.34
- DMAC 0.32
- MACD
- DVAX 0.04
- DMAC -0.00
- Stochastic Oscillator
- DVAX 60.19
- DMAC 41.01
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.